期刊文献+

陆德铭治疗乳腺癌术后转移的经验 被引量:5

Introduction of Professor LU Deming's Experience of Treating Post-operation Metastasis in Breast Cancer
下载PDF
导出
摘要 陆徳铭教授认为乳腺癌患者术后转移多以正虚为其本,余毒旁窜为其标,治疗谨守扶正祛邪大法,以自拟乳癌术后方健脾益气、调摄冲任扶其正,根据病位,随证选用清热解毒、化痰散结之品祛余毒。 Base on Professor LU Deming's experience,the common root cause of post- operation metastasis m breast cancer is asthenia of healthy energy and the manifestation is remained toxicity scurrying and basic therapeutic principle is strengthening body resistance to eliminate pathogenic factors. Professor LU developed Ruai Shuhou Prescription to strengthen body resistance by fortifying the spleen, replenishing qi and regulating Chong - Ren, and eliminate remained toxicity scurrying by clearing heat - tox- icity and dissipating phlegm and resolving masses according to pathological change location and pattern.
作者 刘静
出处 《辽宁中医杂志》 CAS 2014年第12期2544-2545,共2页 Liaoning Journal of Traditional Chinese Medicine
关键词 乳腺癌 术后转移 扶正祛邪 LU Deming breast cancer post - operation metastasis strengthening body resistance to eliminate pathogenic factors
  • 相关文献

参考文献10

  • 1黄哲宙,陈万青,吴春晓,郑荣寿,陈建国,杨念念,王宁,张思维,郑莹.中国女性乳腺癌的发病和死亡现况——全国32个肿瘤登记点2003—2007年资料分析报告[J].肿瘤,2012,32(6):435-439. 被引量:369
  • 2Li J,Zhang BN,Fan JH,et al.A nation-wide multicenter 10-year(1999-2008)retrospective clinical epidemiological study of femal breast cancer in China[J].BMC Cancer,2011,11:364-375.
  • 3王佳玉,徐兵河.绝经后受体阳性晚期乳腺癌内分泌治疗回顾与展望[J].中华医学杂志,2012,92(19):1297-1299. 被引量:4
  • 4汤钊猷.现代肿瘤学[M].3版.上海:复旦大学出版社,2011:890-931.
  • 5陆徳铭工作室,编著.陆徳铭学术经验撷英[M].上海:上海中医药大学出版社,2010:46-50.
  • 6金·李东垣.脾胃论[M].北京:人民卫生出版社,2005
  • 7山东中医学院,河北医学院校释.黄帝内经素问校释[M].北京:人民卫生出版社,1982.2.27.420.
  • 8明·薛己.薛氏医案选[M].北京:人民卫生出版社,1983.
  • 9明·李中梓.医宗必读[M].北京:中国医药科技出版社,2011:321.
  • 10明·张介宾.景岳全书[M].影印本.上海:上海科技出版社,1991:34,915.

二级参考文献26

  • 1杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:279
  • 2全国肿瘤防治研究办公室,全国肿瘤登记中心,卫生部疾病预防控制局.中国肿瘤死亡报告-全国第三次死因回顾抽样调查[M].北京:人民卫生出版社,2010,6.
  • 3Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J, 2008,141:62-68.
  • 4Petru E, Schmahl D. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klin Wochenschr, 1987, 65:959-966.
  • 5Milla-Santos A, Milla L, Rallo L, et al. Phase Ⅲ randomized trial of toremifene vs tamoxifen in hormono-dependant advanced breast cancer. Breast Cancer Res Treat ,2001,65 : 119-124.
  • 6Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase Ⅲ study of the international Letrozole Breast Cancer Group. J Clin Oncol, 2003, 21:2101-2109.
  • 7Nabholtz JM, Buzdar A, PollakM, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol, 2000,18:3758-3767.
  • 8Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therpy for advanced Breast cancer in 668 Postmenopausal women : results of the Tamoxifen or Afimidex Randomized Group Efficacy And Tolerability stuydy. J Clin Oncol, 2000,18:3748-3757.
  • 9Robertson J, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trial. Cancer, 2003, 98:229-238.
  • 10Howell A, Robertson JF, Abram P, et al. Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol, 2004,22:1605-1613.

共引文献503

同被引文献72

引证文献5

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部